Investors Watch List: Regulus Therapeutics Inc. (NASDAQ:RGLS), Orexigen Therapeutics (NASDAQ:OREX), Ohr Pharmaceutical (NASDAQ:OHRP), 3M Company (NYSE:MMM)

On Monday shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) closed at $17.26. Company’s EPS growth for next 5 years is recorded as 39.60%. Regulus Therapeutics Inc. (NASDAQ:RGLS) ‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a report released on Wednesday. They currently have a $41.00 price objective on the stock. Wedbush’s target price points to a potential upside of 148.18% from the stock’s previous close.

On Monday shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) closed at $7.75. Company’s sales growth for last 5 years was 253.90% and EPS growth for next 5 years is recorded as 20.00%. On 26 March, Orexigen Therapeutics, Inc. (NASDAQ:OREX) announced that the European Commission has granted marketing authorization for Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obese), or ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension). This authorization applies to all 28 European Union (EU) member states.

Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) in last trading activity increased 2.55% to close at $2.81. Company weekly performance is -70.36% while its quarterly performance stands at -67.25%. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) is -80.75% away from its 52 week high. On 27 March, Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, wiping out two-thirds of the company's market value on Friday.

On last trading day 3M Company (NYSE:MMM) increased 1.56% to close at $166.05. Its volatility for the week is 1.54% while volatility for the month is 1.39%. MMM's sales growth for past 5 years was 6.60% and its EPS growth for past 5 years was 10.60%. 3M Company (NYSE:MMM) monthly performance is -1.54%. On 26 March, 3M Company (NYSE:MMM) said that, SOFTlab collaborated with 3M and BBDO to realize 3M’s ‘lifelab’ pavilion at SXSW festival 2015.

Leave a Reply

Your email address will not be published. Required fields are marked *